Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2015

Open Access 01-12-2015 | Case report

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report

Authors: Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta Nannini, Micaela Romagnoli, Fabrizio Cantini

Published in: BMC Musculoskeletal Disorders | Issue 1/2015

Login to get access

Abstract

Background

Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.

Case presentation

We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.

Conclusion

This case suggests new perspectives for the treatment of asbestosis and its systemic features.
Literature
1.
Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1666–80.CrossRefPubMed
2.
Cullinan P, Reid P. Pneumoconiosis. Prim Care Resp J. 2013;22:249–52.
3.
Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, et al. Immunological effects of silica and asbestos. Cell Mol Immunol. 2007;4:261–8.PubMed
4.
Pfau JC, Sentissi JJ, Weller G, Putnam EA. Assessment of autoimmune responses associated with asbestos exposure in Libby, Montana, USA. Environ Health Perspect. 2005;113:25–30.CrossRefPubMed
5.
6.
Noonan CW, Pfau JC, Larson TC, Spence MR. Nested case-control study of autoimmune disease in an asbestos-exposed population. Environ Health Perspect. 2006;114:1243–7.CrossRefPubMedPubMedCentral
7.
8.
Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–7.CrossRefPubMedPubMedCentral
9.
Thompson JK, Westbom CM, MacPherson MB, Mossman BT, Heintz NH, Spiess P, et al. Asbestos modulates thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome activation. Part Fibre Toxicol. 2014;11:24.CrossRefPubMedPubMedCentral
10.
Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA. 2008;105:9035–40.CrossRefPubMedPubMedCentral
11.
Ferro A, Zebedeo CN, Davis C, Ng KW, Pfau JC. Amphibole, but not chrysotile, asbestos induces anti-nuclear autoantibodies and IL-17 in C57BL/6 mice. J Immunotoxicol. 2014;11:283–90.CrossRefPubMed
12.
Mattson SB. Caplan's syndrome in association with asbestosis. Report of a case. Scand J Respir Dis. 1971;52:153–61.PubMed
13.
Olsson AR, Skogh T, Axelson O, Wingren G. Occupations and exposures in the work environment as determinants for rheumatoid arthritis. Occup Environ Med. 2004;61:233–8.CrossRefPubMedPubMedCentral
14.
Bartsch P, Salmon J, Mahieu P. Asbestosis and systemic lupus erythematosus. Int Arch Allergy Appl Immunol. 1980;61:28–31.CrossRefPubMed
15.
Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003;21:313–20.PubMed
16.
Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 1993;150:4188–96.PubMed
17.
18.
19.
Portnoy J, Pan T, Dinarello CA, Shannon JM, Westcott JY, Zhang L, et al. Alveolar type II cells inhibit fibroblast proliferation: role of IL-1alpha. Am J Physiol Lung Cell Mol Physiol. 2006;290:L307–316.CrossRefPubMed
20.
Matsuzaki H, Maeda M, Lee S, Nishimura Y, Kumagai-Takei N, Hayashi H, et al. Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis. J Biomed Biotechnol. 2012;2012:492608.CrossRefPubMedPubMedCentral
21.
Ulker O, Yucesoy B, Demir O, Tekin I, Karakaya A. Serum and BAL cytokine and antioxidant enzyme levels at different stages of pneumoconiosis in coal workers. Hum Exp Toxicol. 2008;27:871–7.CrossRefPubMed
22.
Carlsten C, de Roos AJ, Kaufman JD, Checkoway H, Wener M, Seixas N. Cell markers, cytokines, and immune parameters in cement mason apprentices. Arthritis Rheum. 2007;57:147–53.CrossRefPubMed
23.
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416–25.CrossRefPubMed
24.
Cavalli G, Fallanca F, Dinarello CA, Dagna L. Treating pulmonary silicosis by blocking interleukin 1. Am J Respir Crit Care Med. 2015;191(5):596–8.CrossRefPubMed
Metadata
Title
Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
Authors
Laura Niccoli
Emanuele Cassarà
Olga Kaloudi
Carlotta Nannini
Micaela Romagnoli
Fabrizio Cantini
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2015
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-015-0602-6

Other articles of this Issue 1/2015

BMC Musculoskeletal Disorders 1/2015 Go to the issue

Research article

Long-term functional outcome and quality of life following rotationplasty for treatment of malignant tumors

Research article

One-sided hip-preserving and concurrent contralateral total hip arthroplasty for the treatment of bilateral osteonecrosis of the femoral head in different stages: short-medium term outcomes

Research article

The prevalence of axial spondyloarthritis in the UK: a cross-sectional cohort study

Research article

Association between work-related biomechanical risk factors and the occurrence of carpal tunnel syndrome: an overview of systematic reviews and a meta-analysis of current research

Research article

Patient-reported quality of life after primary major joint arthroplasty: a prospective comparison of hip and knee arthroplasty

Research article

Change in pain, disability and influence of fear-avoidance in a work-focused intervention on neck and back pain: a randomized controlled trial